ATE222889T1 - Hydroxamsäure-derivate - Google Patents

Hydroxamsäure-derivate

Info

Publication number: ATE222889T1
Authority: AT; Austria
Prior art keywords: hydroxamic acid; acid derivatives; derivatives; treat; inhibit
Prior art date: 1997-04-04

Application number

AT98915209T

Other languages

English (en)

Inventor

Paul F Jackson

Kevin L Tays

Keith M Maclin

Barbara S Slusher

Original Assignee

Guilford Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-04

Filing date

1998-04-02

Publication date

2002-09-15

1998-04-02 Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc

2002-09-15 Application granted granted Critical

2002-09-15 Publication of ATE222889T1 publication Critical patent/ATE222889T1/de

Links

NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title abstract 2
239000002253 acid Substances 0.000 title abstract 2
102000003958 Glutamate Carboxypeptidase II Human genes 0.000 abstract 3
108090000369 Glutamate Carboxypeptidase II Proteins 0.000 abstract 3
230000000694 effects Effects 0.000 abstract 2
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
230000005856 abnormality Effects 0.000 abstract 1
229930195712 glutamate Natural products 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000017497 prostate disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyridine Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT98915209T 1997-04-04 1998-04-02 Hydroxamsäure-derivate ATE222889T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/825,997 US5962521A (en)	1997-04-04	1997-04-04	Hydroxamic acid derivatives
PCT/US1998/006382 WO1998045256A1 (en)	1997-04-04	1998-04-02	Hydroxamic acid derivatives

Publications (1)

Publication Number	Publication Date
ATE222889T1 true ATE222889T1 (de)	2002-09-15

Family

ID=25245426

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98915209T ATE222889T1 (de)	1997-04-04	1998-04-02	Hydroxamsäure-derivate

Country Status (8)

Country	Link
US (3)	US5962521A (de)
EP (1)	EP0973731B1 (de)
JP (1)	JP2001519809A (de)
AT (1)	ATE222889T1 (de)
AU (1)	AU742418B2 (de)
CA (1)	CA2285906A1 (de)
DE (1)	DE69807455D1 (de)
WO (1)	WO1998045256A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6953668B1 (en)	1992-11-05	2005-10-11	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen
US7105159B1 (en)	1992-11-05	2006-09-12	Sloan-Kettering Institute For Cancer Research	Antibodies to prostate-specific membrane antigen
US7070782B1 (en)	1992-11-05	2006-07-04	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen
US6569432B1 (en) *	1995-02-24	2003-05-27	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen and uses thereof
AU717937B2 (en)	1995-02-24	2000-04-06	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen and uses thereof
US20040253246A1 (en) *	1996-02-23	2004-12-16	Israeli Ron S.	Prostate-specific membrane antigen and uses thereof
US6025344A (en)	1996-06-17	2000-02-15	Guilford Pharmaceuticals Inc.	Certain dioic acid derivatives useful as NAALADase inhibitors
US6395718B1 (en) *	1998-07-06	2002-05-28	Guilford Pharmaceuticals Inc.	Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6444657B1 (en) *	1998-12-31	2002-09-03	Guilford Pharmaceuticals Inc.	Methods for treating certain diseases using naaladase inhibitors
US6528499B1 (en)	2000-04-27	2003-03-04	Georgetown University	Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
AU773915B2 (en) *	1999-04-28	2004-06-10	Georgetown University	Ligands for metabotropic glutamate receptors
US6228888B1 (en)	1999-07-01	2001-05-08	Guilford Pharmaceuticals Inc.	Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors
ATE518540T1 (de)	1999-08-16	2011-08-15	Revaax Pharmaceuticals Llc	Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
US6313159B1 (en)	1999-08-20	2001-11-06	Guilford Pharmaceuticals Inc.	Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
US6348464B1 (en)	1999-11-12	2002-02-19	Guilford Pharmaceuticals, Inc.	Pyrrolecarbonylimino derivatives as naaladase inhibitors
CA2410889A1 (en)	2000-05-30	2001-12-06	Guilford Pharmaceuticals Inc.	Naaladase inhibitors for treating retinal disorders and glaucoma
US20020013295A1 (en) *	2000-05-30	2002-01-31	Slusher Barbara S.	Naaladase inhibitors for treating amyotrophic lateral sclerosis
WO2001092273A2 (en)	2000-05-30	2001-12-06	Guilford Pharmaceuticals Inc.	Benzenedicarboxylic acid derivatives
IT1318636B1 (it) *	2000-07-21	2003-08-27	Roberto Pellicciari	Derivati dell'acido 2- o 3- tenoico ad attivita' antagonista deirecettori del glutammato.
ATE337011T1 (de) *	2001-02-07	2006-09-15	Beth Israel Hospital	Modifizierte psma-liganden und deren verwendung
ES2314087T3 (es) *	2001-03-08	2009-03-16	The Trustees Of The University Of Pennsylvania	Polimeros facialmente anfifilicos como agentes antiinfecciosos.
AU2002256505B2 (en)	2001-05-11	2008-06-26	Eisai Inc.	Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
AU2002357003A1 (en) *	2001-12-28	2003-07-24	Guilford Pharmaceuticals Inc.	Indoles as naaladase inhibitors
WO2003060523A1 (en) *	2002-01-10	2003-07-24	Johns Hopkins University	Imaging agents and methods of imaging naaladase of psma
US20040072815A1 (en) *	2002-02-12	2004-04-15	Koppel Gary A.	Antibiotic composition and method
EP1483283A4 (de)	2002-03-13	2007-04-11	Signum Biosciences Inc	Modulation der proteinmethylierung und phosphoproteinphosphat
EP1988088A1 (de) *	2003-03-03	2008-11-05	Guilford Pharmaceuticals Inc.	Thiolactone
WO2004082634A2 (en)	2003-03-17	2004-09-30	The Trustees Of The University Of Pennsylvania	Facially amphiphilic polymers and oligomers and uses thereof
JP5260877B2 (ja) *	2004-01-23	2013-08-14	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	面に対して両親媒性のポリアリール及びポリアリールアルキニルのポリマー及びオリゴマー並びにそれらの使用
US7923041B2 (en)	2005-02-03	2011-04-12	Signum Biosciences, Inc.	Compositions and methods for enhancing cognitive function
CA2601777A1 (en)	2005-02-03	2006-08-10	Signum Biosciences, Inc.	Compositions and methods for enhancing cognitive function
CA2599205A1 (en) *	2005-02-25	2006-09-08	The Trustees Of The University Of Pennsylvania	Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
EP2097111B1 (de)	2006-11-08	2015-07-15	Molecular Insight Pharmaceuticals, Inc.	Heterodimere von glutaminsäure
PL2187965T3 (pl)	2007-08-17	2020-05-18	Purdue Research Foundation	Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
US8562945B2 (en)	2008-01-09	2013-10-22	Molecular Insight Pharmaceuticals, Inc.	Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof
AU2009239430B2 (en)	2008-04-21	2015-01-22	Signum Biosciences, Inc.	Compounds, compositions and methods for making the same
AU2010260195B2 (en)	2009-06-15	2014-11-20	Molecular Insight Pharmaceuticals, Inc.	Process for production of heterodimers of glutamic acid
CN105130855B (zh)	2009-12-07	2018-05-25	约翰斯霍普金斯大学	二酰基化的羟基胺衍生物及其用途
AU2010328234B2 (en) *	2009-12-07	2016-05-12	Cardioxyl Pharmaceuticals, Inc.	N-acyloxysulfonamide and N-hydroxy-N-acylsulfonamide derivatives
US9951324B2 (en)	2010-02-25	2018-04-24	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
EP2800471A4 (de)	2012-01-06	2015-11-04	Molecular Insight Pharm Inc	Metallkomplexe von poly(carboxyl)aminhaltigen liganden mit einer affinität für carboanhydrase ix
EA201590783A1 (ru)	2012-11-15	2015-11-30	Эндосайт, Инк.	Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EP3939972A1 (de)	2013-01-14	2022-01-19	Molecular Insight Pharmaceuticals, Inc.	Triazinbasierte radiopharmazeutika und strahlungsbildgebungsmittel
EP3456700A1 (de)	2013-10-18	2019-03-20	Deutsches Krebsforschungszentrum	Markierte inhibitoren des prostataspezifischen membranantigens (psma), deren verwendung als kontrastmittel und pharmazeutika zur behandlung von prostatakrebs
EP3533473A3 (de)	2013-11-14	2019-12-18	Endocyte, Inc.	Verbindungen für positronenemissionstomografie
US10188759B2 (en)	2015-01-07	2019-01-29	Endocyte, Inc.	Conjugates for imaging
ES2914123T3 (es)	2017-01-09	2022-06-07	Shuttle Pharmaceuticals Inc	Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
US11584733B2 (en)	2017-01-09	2023-02-21	Shuttle Pharmaceuticals, Inc.	Selective histone deacetylase inhibitors for the treatment of human disease
CN112004537A (zh)	2018-01-09	2020-11-27	穿梭药业公司	用于治疗人疾病的选择性组蛋白去乙酰化酶抑制剂
CN112368024A (zh)	2018-04-17	2021-02-12	恩多塞特公司	治疗癌症的方法
CN114096264B (zh)	2019-05-20	2025-03-14	因多塞特股份有限公司	制备psma缀合物的方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4151172A (en) *	1977-08-11	1979-04-24	E. R. Squibb & Sons, Inc.	Phosphonoacyl prolines and related compounds
US4316896A (en) *	1978-09-07	1982-02-23	Merck & Co., Inc.	Aminoacid derivatives as antihypertensives
US4168267A (en) *	1978-10-23	1979-09-18	E. R. Squibb & Sons, Inc.	Phosphinylalkanoyl prolines
US4337201A (en) *	1980-12-04	1982-06-29	E. R. Squibb & Sons, Inc.	Phosphinylalkanoyl substituted prolines
US4374131A (en) *	1981-04-27	1983-02-15	E. R. Squibb & Sons, Inc.	Amino and substituted amino phosphinyl-alkanoyl compounds
US4716155A (en) *	1981-12-24	1987-12-29	E. R. Squibb & Sons, Inc.	Phosphorus containing compounds and hypotensive use thereof
US4555506A (en) *	1981-12-24	1985-11-26	E. R. Squibb & Sons, Inc.	Phosphorus containing compounds and use as hypotensives
US5140104A (en) *	1982-03-09	1992-08-18	Cytogen Corporation	Amine derivatives of folic acid analogs
US4950738A (en) *	1984-09-13	1990-08-21	Cytogen Corporation	Amine derivatives of anthracycline antibiotics
US4867973A (en) *	1984-08-31	1989-09-19	Cytogen Corporation	Antibody-therapeutic agent conjugates
US4671958A (en) *	1982-03-09	1987-06-09	Cytogen Corporation	Antibody conjugates for the delivery of compounds to target sites
US5156840A (en) *	1982-03-09	1992-10-20	Cytogen Corporation	Amine-containing porphyrin derivatives
US5162512A (en) *	1982-03-09	1992-11-10	Cytogen Corporation	Amine derivatives of anthracycline antibodies
US4560680A (en) *	1982-03-15	1985-12-24	E. R. Squibb & Sons, Inc.	Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4452791A (en) *	1982-03-15	1984-06-05	E. R. Squibb & Sons, Inc.	Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors
US4560681A (en) *	1982-04-22	1985-12-24	E. R. Squibb & Sons, Inc.	Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension
US4448772A (en) *	1982-04-22	1984-05-15	E. R. Squibb & Sons, Inc.	Phosphinylmethylaminocarbonyl imino acid compounds useful for treating hypertension
US4468519A (en) *	1982-06-14	1984-08-28	E. R. Squibb & Sons, Inc.	Esters of phosphinylalkanoyl substituted prolines
US4703043A (en) *	1982-06-23	1987-10-27	E. R. Squibb & Sons, Inc.	Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive
US4616005A (en) *	1982-06-23	1986-10-07	E. R. Squibb & Sons, Inc.	Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4452790A (en) *	1982-06-23	1984-06-05	E. R. Squibb & Sons, Inc.	Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives
US4567166A (en) *	1982-07-14	1986-01-28	E. R. Squibb & Sons, Inc.	Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension
US4444765A (en) *	1982-07-14	1984-04-24	E. R. Squibb & Sons, Inc.	Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension
US4547324A (en) *	1982-07-29	1985-10-15	Stauffer Chemical Company	Method for preparation of N-phosphonomethylglycine
US4741900A (en) *	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
FR2590674B1 (fr) *	1985-11-25	1989-03-03	Inst Nat Sante Rech Med	Nouveaux reactifs de diagnostic
US5190976A (en) *	1986-07-10	1993-03-02	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And University Of Oregon	N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5093525A (en) *	1986-07-10	1992-03-03	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4906779A (en) *	1986-07-10	1990-03-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US5143908A (en) *	1986-11-05	1992-09-01	Merck & Co., Inc.	Antibacterial agents and potentiators of carbapenem antibiotics
US4715994A (en) *	1986-11-05	1987-12-29	Merck & Co., Inc.	Novel antibacterial agents and potentiators of carbapenem antibiotics
US5099063A (en) *	1986-11-05	1992-03-24	Merck & Co., Inc.	Certain phosphinic acid derivatives having antibacterial activity
ZW23187A1 (en) *	1986-12-15	1988-06-29	Hoffmann La Roche	Phosphinic acid derivatives
CA1305177C (en) *	1987-06-30	1992-07-14	Yasufumi Ohfune	Carboxycyclopropylglycine and process for producing the same
JPS6413097A (en) *	1987-07-06	1989-01-17	Mitsubishi Chem Ind	Phosphonic acid derivative
US5041644A (en) *	1987-07-06	1991-08-20	Merck & Co., Inc.	Peptide derivatives of β-chloro-L(Z)-dehydro-glutamic acid
US4849525A (en) *	1987-09-21	1989-07-18	E. R. Squibb & Sons, Inc.	Phosphinylcycloalkylcarbonyl and phosphinylcycloalkenylcarbonyl dipeptides
US4918064A (en) *	1987-10-21	1990-04-17	G. D. Searle & Co.	Phenyl glycines for use in reducing neurotoxic injury
US5871472A (en) *	1987-11-17	1999-02-16	Brown University Research Foundation	Planting devices for the focal release of neuroinhibitory compounds
US4937183A (en) *	1988-02-03	1990-06-26	Cytogen Corporation	Method for the preparation of antibody-fragment conjugates
US5047227A (en) *	1988-02-08	1991-09-10	Cytogen Corporation	Novel and improved antibodies for site specific attachment of compounds
US5030732A (en) *	1988-03-03	1991-07-09	Merck & Co., Inc.	Aminoethylphosphinic acid derivatives
US5162504A (en) *	1988-06-03	1992-11-10	Cytogen Corporation	Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US4966999A (en) *	1988-06-07	1990-10-30	Cytogen Corporation	Radiohalogenated compounds for site specific labeling
EP0347840B1 (de) *	1988-06-23	1995-12-27	Banyu Pharmaceutical Co., Ltd.	Phosphinsäure-Derivate
US5147867A (en) *	1988-10-28	1992-09-15	Merck & Co., Inc.	Phosphorus containing enzyme inhibitors
US5145990A (en) *	1988-10-28	1992-09-08	Merck & Co., Inc.	Phosphorous containing dhp enzyme inhibitors
US4962097A (en) *	1988-10-28	1990-10-09	Merck & Co., Inc.	Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors
US5196510A (en) *	1988-12-29	1993-03-23	Cytogen Corporation	Molecular recognition units
US4994446A (en) *	1989-01-03	1991-02-19	Ramot - University Authority For Applied Research And Industrial Development Ltd.	Drug system
US5136080A (en) *	1989-12-04	1992-08-04	Burroughs Wellcome Co.	Nitrile compounds
US5336689A (en) *	1990-03-02	1994-08-09	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon	Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5262568A (en) *	1990-03-02	1993-11-16	State Of Oregon	Tri- and tetra-substituted guanidines and their use as excitatory amino acid antagonists
US5594007A (en) *	1991-04-18	1997-01-14	Pfizer Inc.	Method for treating spinal cord trauma with phenolic 2-piperidino-1-alkanols
JP2632754B2 (ja) *	1991-05-21	1997-07-23	塩野義製薬株式会社	脳内グルタミン酸遊離抑制剤
DE4141928A1 (de) *	1991-12-19	1993-06-24	Boehringer Mannheim Gmbh	Neue phosphonobernsteinsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5326856A (en) *	1992-04-09	1994-07-05	Cytogen Corporation	Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
AU4267293A (en) *	1992-05-01	1993-11-29	British Biotech Pharmaceuticals Limited	Use of MMP inhibitors
US5489525A (en)	1992-10-08	1996-02-06	The United States Of America As Represented By The Department Of Health And Human Services	Monoclonal antibodies to prostate cells
DE69334071T2 (de)	1992-11-05	2007-10-25	Sloan-Kettering Institute For Cancer Research	Prostata-spezifisches membranantigen
US5449761A (en) *	1993-09-28	1995-09-12	Cytogen Corporation	Metal-binding targeted polypeptide constructs
US5495042A (en) *	1993-11-04	1996-02-27	Cytogen Corporation	Non-alkaline purification of aminophosphonic acids
US5500420A (en)	1993-12-20	1996-03-19	Cornell Research Foundation, Inc.	Metabotropic glutamate receptor agonists in the treatment of cerebral ischemia
US5508273A (en) *	1993-12-30	1996-04-16	Ortho Pharmaceutical Corporation	Substituted phosphonic acids and derivatives useful in treating bone wasting diseases
AU717937B2 (en)	1995-02-24	2000-04-06	Sloan-Kettering Institute For Cancer Research	Prostate-specific membrane antigen and uses thereof
US5795877A (en)	1996-12-31	1998-08-18	Guilford Pharmaceuticals Inc.	Inhibitors of NAALADase enzyme activity
US5804602A (en)	1996-06-17	1998-09-08	Guilford Pharmaceuticals Inc.	Methods of cancer treatment using naaladase inhibitors
US5902817A (en)	1997-04-09	1999-05-11	Guilford Pharmaceuticals Inc.	Certain sulfoxide and sulfone derivatives
US5824662A (en)	1996-09-27	1998-10-20	Guilford Pharmaceuticals Inc.	Treatment of global and focal ischemia using naaladase inhibitors
US5672592A (en)	1996-06-17	1997-09-30	Guilford Pharmaceuticals Inc.	Certain phosphonomethyl-pentanedioic acid derivatives thereof
US5863536A (en)	1996-12-31	1999-01-26	Guilford Pharmaceuticals Inc.	Phosphoramidate derivatives
ID18382A (id) *	1996-09-27	1998-04-02	Guilford Pharm Inc	Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase

1997
- 1997-04-04 US US08/825,997 patent/US5962521A/en not_active Expired - Lifetime
1998
- 1998-04-02 WO PCT/US1998/006382 patent/WO1998045256A1/en not_active Ceased
- 1998-04-02 DE DE69807455T patent/DE69807455D1/de not_active Expired - Lifetime
- 1998-04-02 EP EP98915209A patent/EP0973731B1/de not_active Expired - Lifetime
- 1998-04-02 AU AU69451/98A patent/AU742418B2/en not_active Ceased
- 1998-04-02 CA CA002285906A patent/CA2285906A1/en not_active Abandoned
- 1998-04-02 AT AT98915209T patent/ATE222889T1/de not_active IP Right Cessation
- 1998-04-02 JP JP54287198A patent/JP2001519809A/ja active Pending
1999
- 1999-06-01 US US09/322,688 patent/US6271245B1/en not_active Expired - Fee Related
2001
- 2001-06-15 US US09/880,861 patent/US20010044459A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US5962521A (en)	1999-10-05
JP2001519809A (ja)	2001-10-23
WO1998045256A1 (en)	1998-10-15
CA2285906A1 (en)	1998-10-15
AU6945198A (en)	1998-10-30
US6271245B1 (en)	2001-08-07
US20010044459A1 (en)	2001-11-22
AU742418B2 (en)	2002-01-03
DE69807455D1 (de)	2002-10-02
EP0973731A1 (de)	2000-01-26
EP0973731B1 (de)	2002-08-28

Legal Events

Date	Code	Title	Description
2003-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69807455D1 (de)	2002-10-02	Hydroxamsäure-derivate
ATE226588T1 (de)	2002-11-15	Phosphinsäure-derivate
ES2151467T1 (es)	2001-01-01	Inhibicion de la actividad de la quinasa p38 por aril-ureas.
NO971889L (no)	1997-06-23	Forbindelser og sammensetninger for levering av aktive midler
ATE283848T1 (de)	2004-12-15	Thiarylsulfonamid-hydroxamsäurederivate
PL331598A1 (en)	1999-08-02	Derivatives of hydroxamic and carboxylic acids of mmp activity and tnf inhibiting action
RU94017851A (ru)	1996-01-10	Ингибиторы протеолитических ферментов на основе производных сахарина, фармацевтическая композиция для лечения дегеративных заболеваний
BR9611479A (pt)	1999-07-13	Acidos alfa-iminoidroxâmicos e carboxílicos N-substituídos cíclicos e heterocíclicos
NO985652L (no)	1999-02-09	Anvendelse av naaladaseinhibitorer ved behandling av kreft
MY110104A (en)	1998-01-27	Saccharin derivative proteolytic enzyme inhibitors
DK0994710T4 (da)	2005-10-17	Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
NO20010052L (no)	2001-03-02	NAALADase inhibitorer anvendbare som farmasöytiske forbindelser og preparater
BR9911094A (pt)	2001-10-30	Composições e métodos para o tratamento detosse
TR199901949T2 (xx)	2000-01-21	Lemfositik t�m�rler i�in �areler.
DK0696456T3 (da)	2001-06-25	Kombination af nekrosefremkaldende stoffer med stoffer, som aktiveres af nekroser, til selektiv behandling af tumorer og betændelsessygdomme
DE60122672D1 (de)	2006-10-12	Zusammensetzung zur intestinalen verabreichung
WO2001034596A3 (en)	2002-03-07	Pyrrolecarbonylimino derivatives as naaladase inhibitors
TR199802638T2 (xx)	1999-03-22	Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
ES2187648T3 (es)	2003-06-16	Metodo para la administracion de farmacos para terapia genica.
ES2177324T3 (es)	2002-12-01	Preparaciones de insulina destinadas a la entrega pulmonar y que contiene mentol.
BR9607541A (pt)	1997-12-23	Tratamento de doenças que tem por causa o fator de crescimento da citoquina
TNSN98049A1 (fr)	2005-03-15	Composition pharmaceutique a residence gastrique.
NO20003888L (no)	2000-10-02	Anti-enzympreparater omfattende etylendiamindiravsyre
DK1231908T3 (da)	2004-06-14	Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
WO1999050671A3 (en)	1999-11-18	Toso as a target for drug screening